LAVA Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

LAVA Therapeutics CEO'su Steve Hurly, Jun2019 tarihinde atandı, in görev süresi 5.42 yıldır. şirketin hisselerinin 0.019% doğrudan sahiptir ve bu hisselerin değeri $ 8.05K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 3.8 yıldır.

Anahtar bilgiler

Steve Hurly

İcra Kurulu Başkanı

US$814.4k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	5.4yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive

Jun 02

LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?

Mar 01

LAVA Therapeutics: Assessing A Promising Innovator

Oct 18

LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M

Sep 13

CEO

Steve Hurly (56 yo)

5.4yrs

Görev süresi

US$814,399

Tazminat

Mr. Stephen Allen Hurly, also known as Steve, MSc, MBA, serves as Chief Executive Officer, President and Executive Director at Lava Therapeutics N.V. since June 2019. Mr. Hurly was Chief Executive Officer...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Hurly	CEO, President & Executive Director	5.4yrs	US$814.40k	0.019% $ 8.0k
Fred Powell	Chief Financial Officer	2yrs	Veri yok	0.25% $ 104.6k
Hans van der Vliet	Chief Scientific Officer	7.8yrs	Veri yok	0.29% $ 124.5k
Amy Garabedian	General Counsel & Corporate Secretary	3.3yrs	Veri yok	0.034% $ 14.2k
Wouter Hunnik	VP & Head of Human Resources	3yrs	Veri yok	Veri yok
Ton Adang	Chief Development Officer	7.3yrs	Veri yok	0.024% $ 10.3k
Charles Morris	Chief Medical Officer	1.8yrs	Veri yok	0% $ 0

3.3yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: LVTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Hurly	CEO, President & Executive Director	5.4yrs	US$814.40k	0.019% $ 8.0k
James Noble	Independent Non-Executive Director	2.4yrs	US$52.50k	0% $ 0
Karen Wilson	Independent Non-Executive Director	3.7yrs	US$55.00k	0.038% $ 16.1k
James Allison	Member of Advisory Board	4.8yrs	Veri yok	Veri yok
Jay Backstrom	Non-Executive Director	2.4yrs	US$47.00k	0% $ 0
Kapil Dhingra	Non-Executive Chairman	3.8yrs	US$82.63k	0.11% $ 48.3k
Christy Oliger	Non-Executive Director	1.7yrs	US$37.85k	0% $ 0
Andrea van Elsas	Chairman of Advisory Board	6.6yrs	Veri yok	Veri yok
Padmanee Sharma	Member of Advisory Board	4.8yrs	Veri yok	Veri yok
K. Wittrup	Member of Advisory Board	no data	Veri yok	Veri yok
Dieter Kabelitz	Member of Advisory Board	no data	Veri yok	Veri yok
Madhav Dhodapkar	Member of Advisory Board	no data	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LVTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

LAVA Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

LAVA Therapeutics N.V., Annual General Meeting, Jun 19, 2024

LAVA Therapeutics N.V., Annual General Meeting, Jun 14, 2023

LAVA Therapeutics N.V. Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

LAVA Therapeutics N.V. Announces Board Changes

Less than half of directors are independent

LAVA Therapeutics N.V. Announces Appointment of Fred M. Powell as Chief Financial Officer

Recent updates

Second quarter 2024 earnings released: US$0.31 loss per share (vs US$0.48 loss in 2Q 2023)

Consensus revenue estimates increase by 51%, EPS downgraded

LAVA Therapeutics N.V., Annual General Meeting, Jun 19, 2024

Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive

First quarter 2024 earnings released: US$0.021 loss per share (vs US$0.53 loss in 1Q 2023)

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052

LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?

New major risk - Share price stability

New minor risk - Share price stability

Consensus revenue estimates fall by 50%

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.039 profit in 3Q 2022)

Consensus revenue estimates increase by 101%

Consensus EPS estimates fall by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

LAVA Therapeutics N.V. Provides Updates on Clinical Programs and Extends the Cash Runway

First quarter 2023 earnings released: US$0.53 loss per share (vs US$0.41 loss in 1Q 2022)

LAVA Therapeutics N.V., Annual General Meeting, Jun 14, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

LAVA Therapeutics N.V. Announces Initial Data from the Ongoing Phase 1/2A Clinical Trial of Lava-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

LAVA Therapeutics N.V. Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

LAVA Therapeutics N.V. Announces Board Changes

LAVA Therapeutics N.V. Announces Updated Data from the Phase 1/2A Clinical Trial of LAVA-051 at the 64th American Society of Hematology Annual Meeting and Exposition

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 47%

Less than half of directors are independent

LAVA Therapeutics N.V. Announces Appointment of Fred M. Powell as Chief Financial Officer

LAVA Therapeutics: Assessing A Promising Innovator

Consensus revenue estimates increase by 580%

Consensus revenue estimates increase by 116%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

LAVA Therapeutics N.V. Announces Board Changes

LAVA Therapeutics N.V., Annual General Meeting, Jun 15, 2022

Consensus forecasts updated

LAVA Therapeutics N.V. to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics N.V., Annual General Meeting, Jun 15, 2022

Consensus revenue estimates increase by 686%

LAVA Therapeutics N.V. Announces the Resignation of Ed Smith as Chief Financial Officer

Lava Therapeutics N.V. Announces FDA IND Clearance for Lava-051 for the Treatment of Hematologic Malignancies

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Less than half of directors are independent

LAVA Therapeutics N.V. Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022

LAVA Therapeutics N.V. Announces Dosing of the First Patient in the Phase 1/2A Clinical Trial of LAVA-1207 in Patients with Metastatic Castration-Resistant Prostate Cancer

LAVA Therapeutics N.V. Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference

Consensus forecasts updated

Third quarter 2021 earnings released: €0.29 loss per share

Consensus revenue estimates increase to €909.0k

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş